Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
IPO Year:
Exchange: NYSE
Website: danaher.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $205.00 | Equal Weight → Overweight | Barclays |
| 3/21/2025 | $260.00 | Neutral → Buy | Goldman |
| 3/14/2025 | $260.00 | Hold → Buy | Stifel |
| 2/3/2025 | Outperform → Mkt Perform | Raymond James | |
| 12/23/2024 | Sector Perform | Scotiabank | |
| 12/19/2024 | $275.00 | Buy | Guggenheim |
| 12/13/2024 | $290.00 | Neutral → Buy | BofA Securities |
| 10/31/2024 | $285.00 | Peer Perform → Outperform | Wolfe Research |
| 10/1/2024 | $315.00 | Overweight | Stephens |
| 8/28/2024 | $280.00 | Equal Weight | Wells Fargo |
WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and h
WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-
WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on April 25, 2025 to holders of record on March 28, 2025. This reflects an 18.5% increase over the previous dividend payment of $0.27. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - a
WASHINGTON, Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion, or $1.49 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.14.Revenues increased 2.0% year-over-year to $6.5 billion and non-GAAP core revenue increased 1.0%.Operating cash flow was $2.0 billion and non-GAAP free cash flow was $1.5 billion.Key Full Year 2024 Results Net earnings were $3.9 billion, or $5.29 per diluted common share and non-GAAP ad
WASHINGTON, Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT. For the fourth quarter 2024, estimated revenues are anticipated to increase in the low-single digit percent range year-over-year.Estimated non-GAAP core revenue for the fourth quarter of 2024 is expected to be essentially flat year-over-year, which would be above the Company's previously announced guidance of a low-single digit percent decline.As previously announced, Danaher will hol
WASHINGTON, Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. Y
WASHINGTON, Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on January 31, 2025 to holders of record on December 27, 2024. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagno
WASHINGTON, Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Third Quarter 2024 Results Net earnings were $818 million, or $1.12 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.71.Revenues increased 3.0% year-over-year to $5.8 billion and non-GAAP core revenue increased 0.5%.Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.2 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Our team delivered strong third quarter resu
WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. Y
SD - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
10-Q - DANAHER CORP /DE/ (0000313616) (Filer)
DEFA14A - DANAHER CORP /DE/ (0000313616) (Filer)
DEF 14A - DANAHER CORP /DE/ (0000313616) (Filer)
144 - DANAHER CORP /DE/ (0000313616) (Subject)
8-K - DANAHER CORP /DE/ (0000313616) (Filer)
10-K - DANAHER CORP /DE/ (0000313616) (Filer)
144 - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
4 - DANAHER CORP /DE/ (0000313616) (Issuer)
WASHINGTON, May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Thursday, May 15, 2025 at 10:00 a.m. PT. The event will be simultaneously webcast on www.danaher.com. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology
WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and h
WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-
WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You
The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu BREA, Calif., March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) clearance from the U.S. Food and Drug Administration. The DxC 500i combines advanced technology with an intuitive user interface, ensuring that laboratories of all sizes can meet the growing demands of modern healthcare. With throughput of up to 800 clinical chemistry tests per hour and 100 immunoassay tests per hour, this analyzer delivers precise and
WASHINGTON, Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Wednesday, March 5, 2025 at 10:30 a.m. ET. The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important h
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on April 25, 2025 to holders of record on March 28, 2025. This reflects an 18.5% increase over the previous dividend payment of $0.27. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - a
Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink's CleanCap mRNA capping technology for non-commercial use TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap® mRNA capping technologies to those deve
WASHINGTON, Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted. Key Fourth Quarter 2024 Results Net earnings were $1.1 billion, or $1.49 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $2.14.Revenues increased 2.0% year-over-year to $6.5 billion and non-GAAP core revenue increased 1.0%.Operating cash flow was $2.0 billion and non-GAAP free cash flow was $1.5 billion.Key Full Year 2024 Results Net earnings were $3.9 billion, or $5.29 per diluted common share and non-GAAP ad
Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00
Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00
Stifel upgraded Danaher from Hold to Buy and set a new price target of $260.00
Raymond James downgraded Danaher from Outperform to Mkt Perform
Scotiabank initiated coverage of Danaher with a rating of Sector Perform
Guggenheim initiated coverage of Danaher with a rating of Buy and set a new price target of $275.00
BofA Securities upgraded Danaher from Neutral to Buy and set a new price target of $290.00
Wolfe Research upgraded Danaher from Peer Perform to Outperform and set a new price target of $285.00
Stephens initiated coverage of Danaher with a rating of Overweight and set a new price target of $315.00
Wells Fargo initiated coverage of Danaher with a rating of Equal Weight and set a new price target of $280.00
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud
Patrick Merrin named Chief Operations Officer and Peter Fjellman named Chief Financial Officer Compass Minerals (NYSE:CMP), a leading global provider of essential minerals, today announced the appointment of Patrick Merrin, a seasoned operating executive in the mining industry, as the company's new chief operations officer (COO) and Peter Fjellman, who has decades of experience in senior finance roles, as its new chief financial officer (CFO). Merrin's appointment is effective March 3 and fills the COO position which has been open since June 2024. Fjellman, whose appointment is effective immediately, succeeds Jeff Cathey who has decided to depart Compass Minerals due to personal reasons.
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together under a single roof.WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (C
WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13 years of service. Ms. Sawyer Montgomery, currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair. Rainer Blair com
Move reflects increasing investment in AI as driving force for innovation and productivity.Company will host Innovation Summit in December focused on AI in R&D.WASHINGTON, June 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, today announced the creation of the new role of Chief Data & Artificial Intelligence (AI) Officer and the appointment of Dr. Martin Stumpe to the role. Jose-Carlos Gutierrez-Ramos, Senior Vice President and Chief Science Officer, Danaher, said: "We are delighted to welcome Dr. Stumpe to our team. His extensive experience in leveraging AI to drive scientific and operational progress will be critical in further supporting
New collaborative research center based at University of California, Berkeley, plans to develop platform approaches that can be easily modified to develop gene-editing medicines for hundreds of devastating illnesses Innovative model aims to dramatically reduce preclinical and clinical development time and expense for investigational rare disease therapies that currently struggle to attract fundingNobel laureate Doudna and team to partner with Danaher to oversee center's translational and clinical researchWASHINGTON, Jan. 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) and the Innovative Genomics Institute (IGI) today launched a collaborative center to develop gene-editing therapies fo
NEW YORK, Sept. 28, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, the S&P MidCap 400 and the S&P SmallCap 600 indices: Veralto Corp. (NYSE:VLTO) will be added to the S&P 500 effective prior to the open of trading on Monday, October 2, replacing DXC Technology Co. (NYSE:DXC) which will be moved to the S&P SmallCap 600 effective prior to the open of trading on Tuesday, October 3. DXC Technologies will replace Ebix Inc. (NASD: EBIX) in the S&P SmallCap 600 also effective prior to the open of trading on October 3. S&P 500 &100 constituent Danaher Corp. (NYSE:DHR) is spinning off Veralto in a transaction expected to be completed on October 2. Followin
Investments set foundation for global platform of laboratory-automation technologies serving environmental, agricultural and food-and-beverage applications Battery Ventures, a global, technology-focused investment firm, today announced the creation of a new laboratory-automation platform following recent acquisitions of three complementary companies: Skalar Analytical, PromoChrom Technologies and LCTech. Skalar Analytical, based in Breda, the Netherlands, manufactures a range of chemistry analyzers and laboratory-automation solutions for environmental and agricultural applications. Skalar serves as the foundation for the new platform, while PromoChrom—which is based in Richmond, British
WASHINGTON, June 29, 2022 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members. Mr. Dewan is currently CEO of Arena Holdings Management, a global investment business. From 2003 to 2015, he worked at Tiger Global Management, most recently as Head of Public Equities. Prior to that, Mr. Dewan was a private equity investor at Silver Lake Partners. Mr. Dewan earned his B.S. in Engineering with a Certificate in Applied and Computational Mathematics from Princeton University. Steven M. Rales, Chai
CORALVILLE, Iowa, Sept. 1, 2021 /PRNewswire/ -- Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced today that Demaris Mills has been appointed President of the Company, succeeding Trey Martin, who was promoted to a new position in Genomic Medicine within Danaher, IDT's parent company. The leadership transition comes at a time when IDT is growing its product solutions, expanding its global footprint, has a seasoned leadership team, and has the advantage of the Danaher Business System (DBS) culture. Mills has been with Danaher comp